Navigation Links
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Date:4/9/2008

an adequate return on these investments and our results of operations and financial condition would suffer, (v) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable or sufficient to protect against competitive products, or intellectual property licenses from third parties may be required in the future, (vi) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary product candidates, and (vii) potential competition from existing approved products (branded or generic) or product candidates under development by other companies could negatively impact the commercial potential of the Nektar's product candidates due to such competitive factors as efficacy and safety profiles, pricing, and reimbursement by third party payers These forward- looking statements involve substantial risks and uncertainties, including those risks and uncertainties that are detailed in Nektar's reports and other filings with the SEC including its most recent Annual Report on Form 10-K.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
3. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
4. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
8. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
9. Potential Early Warning System for Lung Cancer Identified
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Phreesia, the patient check-in company, today announced that ... (EHR) software and solutions, has been named a ... practices nationwide that use both SOAPware and Phreesia ... check-in experience. The automated interface between the two ...
... QUINCY, Mass., Oct. 18, 2011 For thousands of nurses, ... the challenge of shopping for the latest in scrub fashions ... Building on the success of the 10 original stores ... now set to open in Tampa, Orlando and Miami FL; ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3An RX for Busy Healthcare Professionals 2An RX for Busy Healthcare Professionals 3
(Date:8/29/2014)... UWDress.com, one of the most famous dress ... of 2014 floor length bridesmaid dresses . Additionally, ... items. According to the company’s marketing specialist, all its ... rate (up to 60 percent off) before September 10. ... special neckline: strapless, one-shoulder, bateau and more. The main ...
(Date:8/29/2014)... to new research presented in a Science Daily article entitled ... Misuse Among Young Adults (8/16), peer pressure should not ... comes to prescription drug abuse. Researchers from Purdue University have ... which influences misuse of prescription drugs is access to friends ... have fun with other using friends. Evidently there is not ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Highly regarded audiologist ... on important hearing health topics. The four reports are titled:, ... The Secrets to Hearing Aid Success , The Top ... Understanding Auditory Processing Disorder in Children , ... because there is a lot of confusion and misinformation about each ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern ... from LAXMed. The medical center is less than 2 miles ... of the 405 freeway. , The LAX clinic marks ... center is located at: 8610 S. Sepulveda Blvd., Suite 204 ... LAX office will provide the same comprehensive services as ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... , TUESDAY, Jan. 12 (HealthDay News) -- An experimental ... study shows. , The drug, DBZ, currently in clinical ... have side effects on the lining of the lower ... to those seen in Barrett,s esophagus, a condition that ...
... two ,good, copies slows age-linked mental decline by half, study ... variant that is good for the heart also appears to ... function and cutting the odds for Alzheimer,s disease, a study ... form of the gene, it reduces the risk of Alzheimer,s ...
... ... and Normal Lives Due to Groundbreaking Gene Therapy, , ... Cambridge, MA (Vocus) January 12, 2010 -- Genetix Pharmaceuticals, a leader ... ALD gene therapy research recently published by its collaboratiors at National Institute of Health and ...
... , WATERTOWN, Mass. , Jan. 12 ... cardiovascular system is also good for the brain, according to ... been braving cold temperatures to get in shape for the ... are encouraging others to keep in shape as well. , ...
... 5, 2010An enzyme that normally helps break down stored ... them more malignant, according to new findings by a ... has focused on the mechanisms leading to cancer formation ... says Benjamin Cravatt, chair of the Scripps Research Department ...
... , , SHENZHEN, China , ... www.htdsmedical.com ) announced that its directors have resolved that up ... sale of its MindUp division to Hiru will be distributed to ... Terry Yuan , HTDS President, said, "In our efforts to maximize ...
Cached Medicine News:Health News:Gene Variant Could Lower Alzheimer's Risk 2Health News:Gene Variant Could Lower Alzheimer's Risk 3Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 2Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 2Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 4Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 2Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 2Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: